PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FULC vs. MELI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between FULC and MELI is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

FULC vs. MELI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%NovemberDecember2025FebruaryMarchApril
-75.63%
223.64%
FULC
MELI

Key characteristics

Sharpe Ratio

FULC:

-0.59

MELI:

1.25

Sortino Ratio

FULC:

-0.29

MELI:

1.78

Omega Ratio

FULC:

0.95

MELI:

1.24

Calmar Ratio

FULC:

-0.61

MELI:

1.59

Martin Ratio

FULC:

-1.12

MELI:

5.59

Ulcer Index

FULC:

49.56%

MELI:

8.97%

Daily Std Dev

FULC:

94.22%

MELI:

40.13%

Max Drawdown

FULC:

-92.70%

MELI:

-89.49%

Current Drawdown

FULC:

-89.38%

MELI:

-7.11%

Fundamentals

Market Cap

FULC:

$177.59M

MELI:

$106.43B

EPS

FULC:

-$0.16

MELI:

$37.79

PS Ratio

FULC:

2.22

MELI:

5.12

PB Ratio

FULC:

0.73

MELI:

24.46

Total Revenue (TTM)

FULC:

$80.00M

MELI:

$16.44B

Gross Profit (TTM)

FULC:

$62.74M

MELI:

$7.55B

EBITDA (TTM)

FULC:

$14.06M

MELI:

$2.56B

Returns By Period

In the year-to-date period, FULC achieves a -30.00% return, which is significantly lower than MELI's 23.46% return.


FULC

YTD

-30.00%

1M

10.77%

6M

-6.27%

1Y

-53.40%

5Y*

-21.46%

10Y*

N/A

MELI

YTD

23.46%

1M

1.62%

6M

0.94%

1Y

53.21%

5Y*

28.65%

10Y*

31.59%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

FULC vs. MELI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FULC
The Risk-Adjusted Performance Rank of FULC is 2525
Overall Rank
The Sharpe Ratio Rank of FULC is 2222
Sharpe Ratio Rank
The Sortino Ratio Rank of FULC is 3232
Sortino Ratio Rank
The Omega Ratio Rank of FULC is 2929
Omega Ratio Rank
The Calmar Ratio Rank of FULC is 1616
Calmar Ratio Rank
The Martin Ratio Rank of FULC is 2727
Martin Ratio Rank

MELI
The Risk-Adjusted Performance Rank of MELI is 8787
Overall Rank
The Sharpe Ratio Rank of MELI is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of MELI is 8484
Sortino Ratio Rank
The Omega Ratio Rank of MELI is 8383
Omega Ratio Rank
The Calmar Ratio Rank of MELI is 9191
Calmar Ratio Rank
The Martin Ratio Rank of MELI is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

FULC vs. MELI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and MercadoLibre, Inc. (MELI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for FULC, currently valued at -0.59, compared to the broader market-2.00-1.000.001.002.003.00
FULC: -0.59
MELI: 1.25
The chart of Sortino ratio for FULC, currently valued at -0.29, compared to the broader market-6.00-4.00-2.000.002.004.00
FULC: -0.29
MELI: 1.78
The chart of Omega ratio for FULC, currently valued at 0.95, compared to the broader market0.501.001.502.00
FULC: 0.95
MELI: 1.24
The chart of Calmar ratio for FULC, currently valued at -0.60, compared to the broader market0.001.002.003.004.00
FULC: -0.61
MELI: 1.59
The chart of Martin ratio for FULC, currently valued at -1.12, compared to the broader market-5.000.005.0010.0015.0020.00
FULC: -1.12
MELI: 5.59

The current FULC Sharpe Ratio is -0.59, which is lower than the MELI Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of FULC and MELI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50NovemberDecember2025FebruaryMarchApril
-0.59
1.25
FULC
MELI

Dividends

FULC vs. MELI - Dividend Comparison

Neither FULC nor MELI has paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
FULC
Fulcrum Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MELI
MercadoLibre, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.19%0.38%0.36%0.52%

Drawdowns

FULC vs. MELI - Drawdown Comparison

The maximum FULC drawdown since its inception was -92.70%, roughly equal to the maximum MELI drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for FULC and MELI. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-89.38%
-7.11%
FULC
MELI

Volatility

FULC vs. MELI - Volatility Comparison

Fulcrum Therapeutics, Inc. (FULC) has a higher volatility of 24.73% compared to MercadoLibre, Inc. (MELI) at 15.44%. This indicates that FULC's price experiences larger fluctuations and is considered to be riskier than MELI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%NovemberDecember2025FebruaryMarchApril
24.73%
15.44%
FULC
MELI

Financials

FULC vs. MELI - Financials Comparison

This section allows you to compare key financial metrics between Fulcrum Therapeutics, Inc. and MercadoLibre, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab